Jan Max, Ebert Benjamin L, Jaiswal Siddhartha
Department of Pathology, Massachusetts General Hospital, Boston, MA.
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA.
Semin Hematol. 2017 Jan;54(1):43-50. doi: 10.1053/j.seminhematol.2016.10.002. Epub 2016 Oct 20.
Cancer results from multistep pathogenesis, yet the pre-malignant states that precede the development of many hematologic malignancies have been difficult to identify. Recent genomic studies of blood DNA from tens of thousands of people have revealed the presence of remarkably common, age-associated somatic mutations in genes associated with hematologic malignancies. These somatic mutations drive the expansion from a single founding cell to a detectable hematopoietic clone. Owing to the admixed nature of blood that provides a sampling of blood cell production throughout the body, clonal hematopoiesis is a rare view into the biology of pre-malignancy and the direct effects of pre-cancerous lesions on organ dysfunction. Indeed, clonal hematopoiesis is associated not only with increased risk of hematologic malignancy, but also with cardiovascular disease and overall mortality. Here we review rapid advances in the genetic understanding of clonal hematopoiesis and nascent evidence implicating clonal hematopoiesis in malignant and non-malignant age-related disease.
癌症源于多步骤发病机制,但许多血液系统恶性肿瘤发生前的癌前状态一直难以识别。最近对数万人血液DNA进行的基因组研究表明,与血液系统恶性肿瘤相关的基因中存在非常常见的、与年龄相关的体细胞突变。这些体细胞突变促使单个起始细胞扩增为可检测到的造血克隆。由于血液的混合性质提供了全身血细胞生成的样本,克隆性造血是对癌前生物学以及癌前病变对器官功能障碍的直接影响的罕见观察。事实上,克隆性造血不仅与血液系统恶性肿瘤风险增加有关,还与心血管疾病和全因死亡率有关。在此,我们综述了对克隆性造血的遗传学认识的快速进展,以及将克隆性造血与恶性和非恶性年龄相关疾病联系起来的新证据。